You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Inivata expects to publish initial data on the assay's detection abilities in lung cancer at the American Association for Cancer Research virtual meeting in July.
The team envisions developing an assay to guide targeted treatment for metastatic castration-resistant prostate cancer patients.
The firm is developing a biomarker panel to detect mutations in mesenchymal cells, with the goal of guiding drug treatment and improving earlier patient intervention.
The firm also aims to commercialize a new version of its PraediCare Dx platform, which will directly detect heterodimer protein complexes on a tumor cell's surface.
Researchers used Mission Bio's Tapestri assay to identify and monitor the evolution of cancer mutations in acute myeloid leukemia in response to targeted treatment.
The firm launched a study this year to validate the new CRC-specific immune-transcriptomic assay, aiming to obtain regulatory approval in Europe.
The method's developers believe that clinicians could use approach to predict how high-grade, serous ovarian cancer patients will respond to chemotherapy.
Kiyatec's cell-based assays model and predict patient therapeutic response to drive cancer drug development and potentially guide treatment.
The firm's "TuMatch" assay integrates patient whole-exome sequencing data and fruit fly models to develop a personalized drug therapy service for cancer patients.
OncoCell aims to enter the cancer prognostic space with its noninvasive immuno-genomics RNA transcriptomics prognostic platform to help differentiate patients with aggressive forms of prostate cancer from patients with indolent disease.